CoChat
Sign Up
Cited by 292Attention Deficit Hyperactivity DisorderPharmaceutical studies and practicesChild and Adolescent Psychosocial and Emotional Development

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Atomoxetine and Methylphenidate Treatment in Children With ADHD: A Prospective, Randomized, Open-Label Trial

KRATOCHVIL, CHRISTOPHER J., HEILIGENSTEIN, JOHN H., DITTMANN, RALF, SPENCER, THOMAS J., BIEDERMAN, JOSEPH, WERNICKE, JOACHIM, NEWCORN, JEFFREY H., CASAT, CHARLES, MILTON, DENÁI, MICHELSON, DAVID·2002·Journal of the American Academy of Child & Adolescent Psychiatry
DOI 10.1097/00004583-200207000-00008
Open this paper in CoChat — free account

Abstract

Objective To assess the comparability of atomoxetine, a new therapy for attention-deficit/hyperactivity disorder (ADHD) and methylphenidate. (Atomoxetine was originally called tomoxetine. The name was recently changed in order to avoid any potential confusion with tamoxifen that might lead to errors in dispensing drug.)Method Children with ADHD were randomized to open-label atomoxetine or methylphenidate for 10 weeks. Response was assessed with the ADHD-IV Rating Scale.Results Two hundred twenty-eight patients were randomized (atomoxetine n = 184, methylphenidate n = 44). Both drugs were associated with marked improvement in inattentive and hyperactive-impulsive symptom clusters as assessed by parents and investigators. No statistically significant differences between treatment groups were observed on the primary outcome measure (investigator-rated ADHD-IV Rating Scale total score: atomoxetine baseline: 39.4 [8.5], endpoint: 20.0 [13.9]; methylphenidate baseline: 37.6 [9.7], endpoint: 19.8 (16.6); p = .66). Safety and tolerability were also similar between the 2 drugs. Discontinuations due to adverse events were 10/184 (5.4%) for atomoxetine and 5/44 (11.4%) for methylphenidate; p = .175.Conclusion These data provide preliminary evidence that atomoxetine is associated with therapeutic effects comparable to those of methylphenidate.

Overview

Integrity signals

Registry

Crossref · 10.1097/00004583-200207000-00008

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 15 references

Research works printed but not linked: 2

  1. Heiligenstein J, Spencer T, Faries DE, Biederman J, Kratochvil CJ, Conners CK (2000), Efficacy of atomoxetine vs. placebo in pediatric outpatients with ADHD (poster). In: Scientific Proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry New York, October
  2. Higgins, 1999, A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder, J Fam Pract, 48, 15

Cited by

Sorted by citations

See all 292

Related

See all

Metadata

Authors
KRATOCHVIL, C. J., HEILIGENSTEIN, J. H., DITTMANN, R., SPENCER, T. J., BIEDERMAN, J., WERNICKE, J., NEWCORN, J. H., CASAT, C., MILTON, D., & MICHELSON, D.
Affiliations
  • University of Nebraska Medical Center (US)
  • Harvard University (US)
Corresponding author
MICHELSON, DAVID
ORCID
Venue
Journal of the American Academy of Child & Adolescent Psychiatry
Publisher
Elsevier BV
Published
2002-07
Volume
41
Issue
7
Pages
776-784
ISSN
0890-8567 (ISSN-L)
DOI
10.1097/00004583-200207000-00008
OpenAlex
W2066201328
Cited by
292
References
15
Citations by year
2025: 4 · 2024: 6 · 2023: 3 · 2022: 6 · 2021: 5 · 2020: 3 · 2019: 7 · 2018: 9 · 2017: 7 · 2016: 4 · 2015: 6 · 2014: 13 · 2013: 6 · 2012: 5
FWCI
21.33
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of the American Academy of Child & Adolescent Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
Keywords
atomoxetine, methylphenidate, attention deficit hyperactivity disorder, children, drug comparison, inattentive symptoms, hyperactive-impulsive symptoms, drug safety and tolerability, adverse events
MeSH terms
Atomoxetine Hydrochloride, Adolescent, Central Nervous System Stimulants, Antidepressive Agents, Attention Deficit Disorder with Hyperactivity, Child, Female, Humans, Male, Methylphenidate, Propylamines, Prospective Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review